Empower Pharmacy Industry Analysis: "Restoring Balance — What the FDA's Peptide Announcement Could Mean for Patient Access and Safety"
Empower Pharmacy published a detailed industry analysis of the FDA's April 16 announcement removing 12 peptides from Category 2 and convening the July 23-24 PCAC meeting. The piece walks through the practical implications for compounding pharmacies, distinguishes Category 2 removal from Section 503A Bulk Drug Substances List inclusion, and emphasizes the gap between regulatory action and clinical access — physicians and patients are pressuring compounders to prepare peptides legally restricted only weeks ago.